Medicare Final CAR-T Policy Eases Coverage Requirements
Product developers and researchers applaud the changes, including dropping "coverage with evidence development" approach.
You may also be interested in...
As CMS brings public attention to process with its national coverage analysis for Alzheimer’s drugs, legislation aims to encourage quick recommendations – and strengthen collaboration with FDA.
Proposed reimbursement decision to be released by 12 January 2022, with a final decision the following April. Biogen's Aduhelm expected to be covered in the interim. Medicare will not consider the cost of treatment in the analysis, but cost may have been a factor in initiating the process.
Biogen/Eisai’s newly-approved Alzheimer’s drug could be headed to CMS’ Medicare advisory committee, which is chaired by vocal drug pricing reform advocate Peter Bach.